Cyclica, Dalton In Drug Development Pact

Cyclica and Dalton have entered a collaboration to identify and develop new drug candidates using advanced computational molecular design with medicinal chemistry and drug development approaches. Cyclica will apply its in silico drug design, optimization services, and extensive databases for a number of lead molecules previously developed by Dalton Medicinal Chemistry, as well as additional compounds. Dalton Pharma Services will synthesize and manufacture quantities of selected drug candidates for analysis and consideration by a global pharmaceutical company’s candidate screening program. Any assets developed will be equally owned by the parties.
 
“It is exciting to see Cyclica’s advanced computational approach to molecule design paired with decades of medicinal chemistry and manufacturing experience from Dalton. This combination could significantly improve the way new drugs are developed,” said Jason Mitakidis, president and chief executive officer of Cyclica.
 
“We believe Cyclica’s expertise and innovations in design are world class,” said Dr. Judd Berman, co-founder of Dalton Medicinal Chemistry. “We look forward to working together as a team to accelerate the discovery of new medicines.”